LDS/Medical Tests/Protean BioDiagnostics Lung HDPCR™ for Non-Small Cell Lung Cancer (NSCLC)

Protean BioDiagnostics Lung HDPCR™ for Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, making it the most common type of lung cancer worldwide. Unlike small cell lung cancer (SCLC), which is aggressive and rapidly progressive, NSCLC generally grows more slowly but is frequently diagnosed at later stages, contributing to high morbidity and mortality. NSCLC includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, each of which may harbor actionable molecular alterations. Molecular profiling has become central to NSCLC management. The NCCN guidelines recommend routine testing for oncogenic drivers including EGFR, BRAF, KRAS, MET, ALK, ROS1, RET, and NTRK fusions, as well as PD-L1 expression for guiding immunotherapy.

The Protean BioDiagnostics Lung HDPCR™ assay is a liquid biopsy test that detects both DNA mutations and RNA fusions across nine clinically relevant genes:

  • DNA mutations: EGFR, KRAS, BRAF
  • RNA fusions: ALK, ROS1, NTRK1/2/3, MET exon 14 skipping, RET

In addition, PD-L1 immunohistochemistry (IHC) can be performed on request to help guide treatment with immune checkpoint inhibitors. Together, these results generate a unique molecular profile that aids in diagnosis, prognosis, treatment selection, and disease monitoring.

  • As an aid in the diagnosis of non-small cell lung cancer
  • Identifies targetable genetic alterations for precision oncology therapies
  • Provides prognostic insights based on mutation profile
  • Helps guide selection of immune checkpoint inhibitors through PD-L1 testing

Results are reported as an interpretive profile correlating molecular alterations with diagnostic, prognostic, and therapeutic implications.

High-risk/positive result: Detection of pathogenic mutations or fusions, associated with increased risk and poorer prognosis; indicates eligibility for targeted therapy.

Negative/low-risk result: No mutations or fusions detected; may require additional tissue-based testing if clinical suspicion remains high.

Not applicable

Next-generation sequencing (NGS) with high-definition PCR technology for DNA and RNA variant detection.

Whole blood, EDTA.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Sputum cytology, lung biopsy, Proteomic blood test for NSCLC.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login